EyePoint Pharmaceuticals/$EYPT
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Ticker
$EYPT
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
165
ISIN
US30233G2093
Website
EYPT Metrics
BasicAdvanced
$761M
-
-$2.43
1.60
-
Price and volume
Market cap
$761M
Beta
1.6
52-week high
$11.76
52-week low
$3.91
Average daily volume
930K
Financial strength
Current ratio
7.846
Quick ratio
7.645
Long term debt to equity
7.478
Total debt to equity
8.137
Interest coverage (TTM)
-11,526.43%
Profitability
EBITDA (TTM)
-159.748
Gross margin (TTM)
-188.54%
Net profit margin (TTM)
-261.91%
Operating margin (TTM)
-287.94%
Effective tax rate (TTM)
-0.06%
Revenue per employee (TTM)
$340,000
Management effectiveness
Return on assets (TTM)
-29.16%
Return on equity (TTM)
-53.54%
Valuation
Price to revenue (TTM)
11.942
Price to book
2.55
Price to tangible book (TTM)
2.59
Price to free cash flow (TTM)
-4.423
Free cash flow yield (TTM)
-22.61%
Free cash flow per share (TTM)
-250.05%
Growth
Revenue change (TTM)
12.04%
Earnings per share change (TTM)
31.44%
3-year revenue growth (CAGR)
12.93%
3-year earnings per share growth (CAGR)
4.85%
What the Analysts think about EYPT
Analyst ratings (Buy, Hold, Sell) for EyePoint Pharmaceuticals stock.
Bulls say / Bears say
EyePoint Pharmaceuticals has received a consensus 'Strong Buy' rating from eight analysts, with an average price target of $24.75, indicating a potential upside of over 150% from the current price. (stockanalysis.com)
The company has completed enrollment in its pivotal Phase 3 LUGANO trial of DURAVYU™ for the treatment of wet age-related macular degeneration, a significant milestone in its clinical development pipeline. (eyepointpharma.com)
EyePoint Pharmaceuticals reported a 23.9% average quarterly increase in revenue over the last four quarters, demonstrating strong financial growth. (indmoney.com)
Despite increasing revenue, EyePoint Pharmaceuticals has experienced a 25.1% average quarterly decrease in net profit over the last three quarters, indicating financial challenges. (indmoney.com)
The company's stock price has been volatile, with a 29% decline in December 2024, raising concerns about market stability. (simplywall.st)
EyePoint Pharmaceuticals reported a quarterly loss of $0.54 per share, missing the Zacks Consensus Estimate of a loss of $0.48, which may indicate operational inefficiencies. (zacks.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
EYPT Financial Performance
Revenues and expenses
EYPT Earnings Performance
Company profitability
EYPT News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for EyePoint Pharmaceuticals stock?
EyePoint Pharmaceuticals (EYPT) has a market cap of $761M as of July 11, 2025.
What is the P/E ratio for EyePoint Pharmaceuticals stock?
The price to earnings (P/E) ratio for EyePoint Pharmaceuticals (EYPT) stock is 0 as of July 11, 2025.
Does EyePoint Pharmaceuticals stock pay dividends?
No, EyePoint Pharmaceuticals (EYPT) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next EyePoint Pharmaceuticals dividend payment date?
EyePoint Pharmaceuticals (EYPT) stock does not pay dividends to its shareholders.
What is the beta indicator for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals (EYPT) has a beta rating of 1.6. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.